The role of luteal support during IVF: a qualitative systematic review

References

• Radesic B, Tremellen K. Ooocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates. Hum Reprod. 2011;26:3437–3442.
   PubMed Web of Science ®Google Scholar
• Smitz J, Bourgain C, Van Waesberghe L, et al. A prospective randomized study on estradiol valerate supplementation in addition to intravaginal micronized progesterone in buserelin and HMG-induced superovulation. Hum Reprod. 1993;8:40–45.
   PubMed Web of Science ®Google Scholar
• Fauser BC, Devroey P. Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends Endocrinol Metab. 2003;14:236–242.
   PubMed Web of Science ®Google Scholar
• Garcia J, Jones GS, Acosta Jr. AA, et al. Corpus luteum function after follicle aspiration for oocyte retrieval. Fertil Steril. 1981;36:565–572.
   PubMed Web of Science ®Google Scholar
• Smitz J, Devroey P, Camus M, et al. The luteal phase and early pregnancy after combined GnRH-agonist/HMG treatment for superovulation in IVF or GIFT. Hum Reprod. 1988;3:585–590.
   PubMed Web of Science ®Google Scholar
• Elter K, Nelson LR. Use of third generation gonadotropin-releasing hormone antagonists in in vitro fertilization-embryo transfer: a review. Obstet Gynecol Surv. 2001;56:576–588.
   PubMed Web of Science ®Google Scholar
• Beckers NG, Macklon NS, Eijkemans MJ, et al. Comparison of the nonsupplemented luteal phase characteristics after recombinant (r)HCG, rLH or GnRH agonist for oocyte maturation in IVF. Hum Reprod. 2002;17:S55.
   PubMed Web of Science ®Google Scholar
• Beckers NG, Macklon NS, Eijkemans MJ, et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab. 2003;88:4186–4192.
   PubMed Web of Science ®Google Scholar
• Penarrubia J, Balasch J, Fabregues F, et al. Human chorionic gonadotrophin luteal support overcomes luteal phase inadequacy after gonadotrophin-releasing hormone agonist-induced ovulation in gonadotrophin-stimulated cycles. Hum Reprod. 1998;13:3315–3318.
   PubMed Web of Science ®Google Scholar
• Albano C, Grimbizis G, Smitz J, et al. The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix. Fertil Steril. 1998;70:357–359.
   PubMed Web of Science ®Google Scholar
• Fatemi HM. The luteal phase after 3 decades of IVF: what do we know? BioMedicine Online. 2009;19:S4331.
   PubMedGoogle Scholar
• Csapo AI, Pulkkinen MO, Wiest WG. Effects of luteectomy and progesterone replacement therapy in early pregnant patients. Am J Obstet Gynecol. 1973;115:759–765.
   PubMed Web of Science ®Google Scholar
• Nosarka S, Kruger T, Siebert I, et al. Luteal phase support in in vitro fertilization: metaanalysis of randomized trials. Gynecol Obstet Invest. 2005;60:67–74.
   PubMed Web of Science ®Google Scholar
• van der Linden M, Buckingham K, Farquhar C, et al. Luteal phase support for assisted reproduction cycles. Cochrane Database of Syst Rev. 2011:10;CD009154.
   PubMed Web of Science ®Google Scholar
• Van der Linden M, Buckingham K, Farquhar C, et al. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2015:7;CD009154.
   PubMed Web of Science ®Google Scholar
• Nahoul K, Dehennin L, Jondet M, et al. Profiles of plasma estrogens, progesterone and their metabolites after oral or vaginal administration of estradiol or progesterone. Maturitas. 1993;16:185–202.
   PubMed Web of Science ®Google Scholar
• Vaisbuch E, Leong M, Shoham Z. Progesterone support in IVF: is evidence-based medicine translated to clinical practice? A worldwide web-based survey. Reprod Biomed Online. 2012;25:139–145.
   PubMed Web of Science ®Google Scholar
• Schindler AE. Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium. Maturitas. 2009;65:S3–S11.
   PubMed Web of Science ®Google Scholar
• Cabeza M, Heuze Y, Sanchez A, et al. Recent advances in structure of progestins and their binding to progesterone receptors. J Enzyme Inhib Med Chem. 2015;30:152–159.
   PubMed Web of Science ®Google Scholar
• Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005;8:3–63.
   PubMed Web of Science ®Google Scholar
• Chakravarty BN, Shirazee HH, Dam P, et al. Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. J Steroid Biochem Mol Biol. 2005;97:416–420.
   PubMed Web of Science ®Google Scholar
• Ganesh A, Chakravorty N, Mukherjee R, et al. Comparison of oral dydrogestrone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertil Steril. 2011;95:1961–1965.
   PubMed Web of Science ®Google Scholar
• Barbosa MW, Silva LR, Navarro PA, et al. Dydrogesterone vs progesterone for luteal-phase support: systematic review and meta-analysis of randomized controlled trials. Ultrasound Obstet Gynecol. 2016;48:161–170.
   PubMed Web of Science ®Google Scholar
• Tournaye H, Sukhikh GT, Kahler E, et al. A phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Hum Reprod. 2017;32:1019–1027.
   PubMed Web of Science ®Google Scholar
• Griesinger G, Blockeel C, Sukhikh GT, et al. Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial. Hum Reprod. 2018;133:2212–2221.
   Google Scholar
• Rashidi BH, Ghazizadeh M, Nejad EST, et al. Oral dydrogesterone for luteal support in frozen-thawed embryo transfer artificial cycles: A pilot randomized controlled trial. Asian Pac J Reprod. 2016;5:490–494.
   Google Scholar
• Zarei A, Sohail P, Parsanezhad ME, et al. Comparison of four protocols for luteal phase support in frozen-thawed Embryo transfer cycles: a randomized clinical trial. Arch Gynecol Obstet. 2017;295:239–246.
   PubMed Web of Science ®Google Scholar
• Tomic V, Tomic J, Klaic DZ, et al. Oral dydrogesterone versus vaginal progesterone gel in the luteal phase support: randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2015;186:49–53.
   PubMed Web of Science ®Google Scholar
• Saharkhiz N, Zamaniyan M, Salehpour S, et al. A comparative study of dydrogesterone and micronized progesterone for luteal phase support during in vitro fertilization (IVF) cycles. Gynecol Endocrinol. 2016;32:213–217.
   PubMed Web of Science ®Google Scholar
• Zaqout M, Aslem E, Abuqamar M, et al. The impact of oral intake of dydrogesterone on fetal heart development during early pregnancy. Pediatr Cardiol. 2015;36:1483–1488.
   PubMed Web of Science ®Google Scholar
• Child T, Leonard SA, Evans JS, et al. Systematic review of the clinical efficacy of vaginal progesterone for luteal phase support in assisted reproductive technology cycles. Reprod Biomed Online. 2018;36:630–645.
   PubMed Web of Science ®Google Scholar
• Bourgain C, Devroey P, Van Waesberghe L, et al. Effects of natural progesterone on the morphology of the endometrium in patients with primary ovarian failure. Hum Reprod. 1990;5:537–543.
   PubMed Web of Science ®Google Scholar
• de Ziegler D, Bergeron C, Cornel C, et al. Effects of luteal estradiol on the secretory transformation of human endometrium and plasma gonadotropins. J Clin Endocrinol Metab. 1992;74:322–331.
   PubMed Web of Science ®Google Scholar
• Cicinelli E, de Ziegler D, Morgese S, et al. First uterine pass effect is observed when estradiol is placed in the upper but not lower third of the vagina. Fertil Steril. 2004;81:1414–1416.
   PubMed Web of Science ®Google Scholar
• Cicinelli E, de Ziegler D. Transvaginal progesterone: evidence for a new functional ‘‘portal system’’ flowing from the vagina to the uterus. Hum Reprod Update. 1999;5:365–372.
   PubMed Web of Science ®Google Scholar
• Bergh C, Lindenberg S. and Nordic Crinone Study Group. A prospective randomized multicentre study comparing vaginal progesterone gel and vaginal micronized progesterone tablets for luteal support after in vitro fertilization/intracytoplasmic sperm injection. Hum Reprod. 2012;27:3467–3473.
   PubMed Web of Science ®Google Scholar
• Kleinstein J. Efficacy and tolerability of vaginal progesterone capsules (Utrogest 200) compared with progesterone gel (Crinone 8%) for luteal phase support during assisted reproduction. Fertil Steril. 2005;83:1641–1649.
   PubMed Web of Science ®Google Scholar
• Simunic V, Tomic V, Tomic J, et al. Comparative study of the efficacy and tolerability of two vaginal progesterone formulations, Crinone 8% gel and Utrogestan capsules, used for luteal support. Fertil Steril. 2007;87:83–87.
   PubMed Web of Science ®Google Scholar
• Polyzos NP, Messini CI, Papanikolaou EG, et al. Vaginal progesterone gel for luteal phase support in IVF/ICSI cycles: a meta-analysis. Fertil Steril. 2010;94:2083–2087.
   PubMed Web of Science ®Google Scholar
• Doody KJ, Schnell VL, Foulk RA, et al. Endometrin for luteal phase support in a randomized, controlled, open-label, prospective in-vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation. Fertil Steril. 2009;91:1012–1017.
   PubMed Web of Science ®Google Scholar
• Ng EH, Chan CC, Tang OS, et al. A randomized comparison of side effects and patient convenience between Cyclogest suppositories and Endometrin tablets used for luteal phase support in IVF treatment. Eur J Obstet Gynecol Reprod Biol. 2007;131:182–188.
   PubMed Web of Science ®Google Scholar
• Ng EH, Miao B, Cheung W, et al. A randomised comparison of side effects and patient inconvenience of two vaginal progesterone formulations used for luteal support in in vitro fertilisation cycles. Eur J Obstet Gynecol Reprod Biol. 2003;111:50–54.
   PubMed Web of Science ®Google Scholar
• Tomic V, Tomic J, Klaic DZ. Oral micronized progesterone combined with vaginal progesterone gel for luteal support. Gynecol Endocrinol. 2011;27:1010–1013.
   PubMed Web of Science ®Google Scholar
• de Ziegler D, Pirtea P, Andersen CY, et al. Role of gonadotropin-releasing hormone agonists, human chorionic gonadotropin (hCG), progesterone, and estrogen in luteal phase support after hCG triggering, and when in pregnancy hormonal support can be stopped. Fertil Steril. 2018;109:749–755.
   PubMed Web of Science ®Google Scholar
• Dal Prato L, Bianchi L, Cattoli M, et al. Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial. Repro Biomed Online. 2008;16:361–367.
   PubMed Web of Science ®Google Scholar
• Yanushpolsky E, Hurwitz S, Greenberg L, et al. Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization-embryo transfer cycles: a prospective randomized study. Fertil Steril. 2010;94:2596–2599.
   PubMed Web of Science ®Google Scholar
• Kahraman S, Karagozoglu SH, Karlikaya G. The efficiency of progesterone vaginal gel versus intramuscular progesterone for luteal phase supplementation in gonadotropin-releasing hormone antagonist cycles: a prospective clinical trial. Fertil Steril. 2010;94:761–763.
   PubMed Web of Science ®Google Scholar
• Berger BM, Ezcurra D, Phillips JA, et al. Crinone 8% (progesterone gel) vs. progesterone capsules vs. intramuscular progesterone for luteal phase support in older women. Fertil Steril. 2009;92:S23.
   Google Scholar
• Zarutskie PW, Phillips JA. A meta-analysis of the route of administration of luteal phase support in assisted reproductive technology: vaginal vs. intramuscular progesterone. Fertil Steril. 2009;92:163–169.
   PubMed Web of Science ®Google Scholar
• Silverberg KM, Vaughn TC, Hansard LJ, et al. Vaginal (Crinone 8%) gel vs. intramuscular progesterone in oil for luteal phase support in in vitro fertilization: a large prospective trial. Fertil Steril. 2012;97:344–348.
   PubMed Web of Science ®Google Scholar
• Devine K, Richter KS, Widra EA, et al. Vitrified blastocyst transfer cycles with the use of only vaginal progesterone replacement with Endometrin have inferior ongoing pregnancy rates: results from the planned interim analysis of a three-arm randomized controlled noninferiority trial. Fertil Steril. 2018;109:266–275.
   PubMed Web of Science ®Google Scholar
• Levine H. Luteal support with Crinone 8% in 1827 women undergoing assisted reproductive technology (ART) procedures. Fertil Steril. 2000;74:S152–S153.
   PubMed Web of Science ®Google Scholar
• Beltsos AN, Sanchez MD, Doody KJ, et al. Patients' administration preferences: progesterone vaginal insert [Endometrin®] compared to intramuscular progesterone for luteal phase support. Reprod Health. 2014;11:78.
   PubMed Web of Science ®Google Scholar
• Bernardo-Escudero R, Cortés-Bonilla M, Alonso-Campero R, et al. Observational study of the local tolerability of injectable progesterone microspheres. Gynecol Obstet Invest. 2012;73:124–129.
   PubMed Web of Science ®Google Scholar
• Veysman B, Vlahos I, Oshva L. Pneumonitis and eosinophilia after in vitro fertilization treatment. Ann Emerg Med. 2006;47:472–475.
   PubMed Web of Science ®Google Scholar
• Mitwally MF, Diamond MP, Abuzeid M. Vaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization-embryo transfer. Fertil Steril. 2010;93:554–569.
   PubMed Web of Science ®Google Scholar
• Sator M, Radicioni M, Cometti B, et al. Pharmacokinetics and safety profile of a novel progesterone aqueous formulation administered by the s.c. route. Gynecol Endocrinol. 2013;29:205–208.
   PubMed Web of Science ®Google Scholar
• de Ziegler D, Sator M, Binelli D, et al. A randomized trial comparing the endometrial effects of daily subcutaneous administration of 25 mg and 50 mg of progesterone in aqueous preparation. Fertil Steril. 2013;100:860–866.
   PubMed Web of Science ®Google Scholar
• Lockwood G, Griesinger G, Cometti B, et al. Subcutaneous progesterone versus vaginal progesterone gel for luteal phase support in in vitro fertilization: a noninferiority randomized controlled study. Fertil Steril. 2014;101:112–119.e113.
   PubMed Web of Science ®Google Scholar
• Baker VL, Jones CA, Doody K, et al. A randomized, controlled trial comparing the efficacy and safety of aqueous subcutaneous progesterone with vaginal progesterone for luteal phase support of in vitro fertilization. Hum Reprod. 2014;29:2212–2220.
   PubMed Web of Science ®Google Scholar
• Venturella R, Vaiarelli A, Buffo L, et al. Progesterone for preparation of the endometrium for frozen-thawed blastocyst transfer in vitro fertilization cycles: a prospective study on patients' opinions on a new subcutaneous formulation. Gynecol Endocrinol. 2018;34:766–771.
   PubMed Web of Science ®Google Scholar
• Beckers NG, Laven JS, Eijkemans MJ, et al. Follicular and luteal phase characteristics following early cessation of gonadotrophin-releasing hormone agonist during ovarian stimulation for in-vitro fertilization. Hum Reprod. 2000;15:43–49.
   PubMed Web of Science ®Google Scholar
• Williams SC, Oehninger S, Gibbons WE, et al. Delaying the initiation of progesterone supplementation results in decreased pregnancy rates after in vitro fertilization: a randomized, prospective study. Fertil Steril. 2001;76:1140–1143.
   PubMed Web of Science ®Google Scholar
• Mochtar MH, Van Wely M, Van der Veen F. Timing luteal phase support in GnRH agonist down-regulated IVF/embryo transfer cycles. Hum Reprod. 2006;21:905–908.
   PubMed Web of Science ®Google Scholar
• Feichtinger M, Hajek J, Kemter P, et al. Effect of luteal phase support comparing early (Day 1) and Late (Day 4) initiation with pregnancy rates. Reproduktionsmed Endokrinol. 2011;8:288–290.
   Google Scholar
• Connell MT, Szatkowski JM, Terry N, et al. Timing luteal support in assisted reproductive technology: a systematic review. Fertil Steril. 2015;103:939–946.
   PubMed Web of Science ®Google Scholar
• Schmidt KL, Ziebe S, Popovic B, et al. Progesterone supplementation during early gestation after in vitro fertilization has no effect on the delivery rate. Fertil Steril. 2001;75:337–341.
   PubMed Web of Science ®Google Scholar
• Nyboe Andersen A, Popovic-Todorovic B, Schmidt KT, et al. Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Hum Reprod. 2002;17:357–361.
   PubMed Web of Science ®Google Scholar
• Liu XR, Mu HQ, Shi Q, et al. The optimal duration of progesterone supplementation in pregnant women after IVF/ICSI: a meta-analysis. Reprod Biol Endocrinol. 2012;10:107
   PubMed Web of Science ®Google Scholar